These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

948 related items for PubMed ID: 24038019

  • 21. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
    Rao MS.
    J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
    [Abstract] [Full Text] [Related]

  • 22. Clinical role of direct renin inhibition in hypertension.
    Taylor AA, Pool JL.
    Am J Ther; 2012 May; 19(3):204-10. PubMed ID: 21317620
    [Abstract] [Full Text] [Related]

  • 23. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis.
    Chrysant SG, Murray AV, Hoppe UC, Dattani D, Patel S, Hsu H, Zhang J.
    Curr Med Res Opin; 2008 Apr; 24(4):1039-47. PubMed ID: 18307835
    [Abstract] [Full Text] [Related]

  • 24. Renin inhibition with aliskiren: where are we now, and where are we going?
    Azizi M, Webb R, Nussberger J, Hollenberg NK.
    J Hypertens; 2006 Feb; 24(2):243-56. PubMed ID: 16508564
    [Abstract] [Full Text] [Related]

  • 25. [Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].
    Horký K.
    Vnitr Lek; 2010 Feb; 56(2):120-6. PubMed ID: 20329582
    [Abstract] [Full Text] [Related]

  • 26. Aliskiren vs. other antihypertensive drugs in the treatment of hypertension: a meta-analysis.
    Chen Y, Meng L, Shao H, Yu F.
    Hypertens Res; 2013 Mar; 36(3):252-61. PubMed ID: 23154589
    [Abstract] [Full Text] [Related]

  • 27. What is the role of direct renin inhibitors in the treatment of the hypertensive diabetic patient?
    de la Sierra A, Salazar J.
    Adv Ther; 2011 Sep; 28(9):716-27. PubMed ID: 21809181
    [Abstract] [Full Text] [Related]

  • 28. Inhibiting the renin-angiotensin system: why and in which patients.
    Berra K, Miller NH.
    J Am Acad Nurse Pract; 2009 Jan; 21(1):66-75. PubMed ID: 19125897
    [Abstract] [Full Text] [Related]

  • 29. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A, Divchev D, Luchtefeld M, Schieffer B.
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Direct renin inhibition: extricating facts from façades.
    Juncos L.
    Ther Adv Cardiovasc Dis; 2013 Jun; 7(3):153-67. PubMed ID: 23487045
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Aliskiren in the management of hypertension.
    Barrios V, Escobar C.
    Am J Cardiovasc Drugs; 2010 Jun; 10(6):349-58. PubMed ID: 21090828
    [Abstract] [Full Text] [Related]

  • 34. [Renin and the heart].
    Ural D, Cetin M.
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():23-7. PubMed ID: 20019473
    [Abstract] [Full Text] [Related]

  • 35. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
    Abassi Z, Armaly Z, Nakhoul F, Hoffman A.
    Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
    [Abstract] [Full Text] [Related]

  • 36. Novel drugs targeting hypertension: renin inhibitors.
    Danser AH.
    J Cardiovasc Pharmacol; 2007 Aug; 50(2):105-11. PubMed ID: 17703126
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Update on role of direct renin inhibitor in diabetic kidney disease.
    Dhakarwal P, Agrawal V, Kumar A, Goli KM, Agrawal V.
    Ren Fail; 2014 Jul; 36(6):963-9. PubMed ID: 24678880
    [Abstract] [Full Text] [Related]

  • 39. Direct renin inhibition: from pharmacological innovation to novel therapeutic opportunities.
    Volpe M, Pontremoli R, Borghi C.
    High Blood Press Cardiovasc Prev; 2011 Sep 01; 18(3):93-105. PubMed ID: 21950781
    [Abstract] [Full Text] [Related]

  • 40. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG.
    J Indian Med Assoc; 2009 Mar 01; 107(3):178-82. PubMed ID: 19810392
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 48.